Prioritizing Safety In CAR-T Therapy: Patient Monitoring With Cerba Research's Testing Portfolio

Navigating the Frontier: Addressing the Need for Patient Safety Monitoring

Recent strides in knowledge and technology have significantly enhanced our capacity to precisely manipulate cells and genes for therapeutic purposes, ushering in the era of Cell and Gene Therapy (CGT). A major breakthrough CGT has been the chimeric antigen receptor T (CAR-T) cells to treat cancer. Cell and gene therapies entail certain risks requiring careful attention and monitoring to safeguard patient safety.

Retroviral vectors (RVV) and lentiviral vectors (LVV) used to produce CAR-T cells, are modified from wild viruses, and do not replicate. It is theoretically possible for LVV/RVV to recombine with other viruses genetically, thereby restoring their ability to replicate. These potentially harmful viruses are referred to as replication-competent lenti-/retroviruses (RCL/RCR).

We suggest a novel approach to patient safety monitoring by combining breakthrough flow cytometry and genomics solutions.